VCR1

Verseon is a clinical-stage pharmaceutical company that utilizes a proprietary drug discovery platform combining deep quantum physics modeling with artificial intelligence (VersAI™). The company's approach, which it terms "Deep Quantum Modeling," allows for the systematic design of novel small-molecule therapeutics that are chemically distinct from existing drugs. Verseon's pipeline is focused on major unmet needs in cardiometabolic disorders and oncology. Its lead programs include precision oral anticoagulants (PROACs) designed to prevent clots without the high bleeding risk of current treatments, and oral therapies for diabetic macular edema. The company operates through several subsidiaries, including VCR1, which manages its clinical trial operations in Australia.